课题基金 / 基金详情

Identifying Early Markers of Autism Spectrum Disorder Based on Patterns of Medical Symptoms and Healthcare Service

Identifying Early Markers of Autism Spectrum Disorder Based on Patterns of Medical Symptoms and Healthcare Service
根据医疗症状和医疗服务模式识别自闭症谱系障碍的早期标志
批准号:
9895898
负责人:
Guodong Liu
金额:
$23.75万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-03-01 至 2021-12-31

项目摘要

项目成果

Guodong Liu的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 自闭症谱系障碍(ASD)是一种复杂的大脑障碍,其特征是语言和非语言能力的困难。 言语社会互动和重复行为模式。在大约400万出生的婴儿中, 美国根据最近的疾病控制和预防中心的数据,每年约有6万人被诊断为ASD,即每59名儿童中就有1人被诊断为ASD 估算早在12个月大时就进行的干预已被证明是有效的, 诊断对于ASD干预的成功至关重要。然而,在确定 儿童在早期患ASD的风险很高。尽管普遍筛查可以改善早期发现, ASD,各种障碍阻止了它被广泛采用。 几十年的深入研究不仅确定了行为ASD标记, 许多其他风险因素,如遗传变异,家庭和兄弟姐妹的病史,大脑异常, 低出生体重,以及父亲和母亲分娩时的年龄。此外,还有不确定的证据表明, 一些医疗条件,如中耳炎,感染,癫痫,胃肠道问题,出生 并发症以及发育和生理里程碑的延迟可能与ASD相关,但 可能在ASD的标志性行为症状发作之前就表现出来。尽管事实上, 这些医学症状可能不够敏感而不能用作ASD诊断的可行标记, 结合在一起,他们有希望在任何自闭症之前, 现有的ASD筛查工具目前能够。消除延迟诊断将允许 通过早期干预优化结果。据我们所知, 收集这些积累的知识。通过利用一个大型的,全国性的,纵向的,私人的 保险医疗索赔数据库(MarketScan®)和Medicaid索赔数据库(Medicaid Analytic eXtract 或MAX),我们将全面调查某些医学症状和医疗保健的集体作用, 服务使用模式作为预测ASD风险的早期标志。 如果成功,这项研究将展示一种改善ASD风险预测的新方法, 可以建立一个基于医疗索赔的ASD监测系统。在后台工作,这样一个系统 可以筛选大量儿童的电子医疗索赔记录,寻找模式 指出潜在的风险,并确定儿童进一步的亲自评估时,他们的ASD风险 跨过了一个临界点这将最终促进ASD的早期检测,从而最终改善ASD的诊断。 早期干预治疗的影响。
英文摘要
ABSTRACT Autism Spectrum Disorder (ASD) is a complex brain disorder marked by difficulties in verbal and non- verbal social interactions and patterns of repetitive behaviors. Of the approximately 4 million babies born in the U.S. each year, about 60,000 will be diagnosed with ASD, or about 1 in 59 children based on the recent CDC estimate. Interventions delivered as early as 12 months of age have been shown to be effective, and early diagnosis is critical to the success of ASD interventions. However, there has been little progress on identifying children at high risk for ASD at an early age. Although universal screening could improve the early detection of ASD, various barriers have kept it from being widely adopted. Decades of in-depth research have not only identified behavioral ASD markers but have also shed light on many other risk factors, such as genetic variants, family and siblings’ medical history, brain abnormalities, low birth weight, and paternal and maternal ages at childbirth. In addition, there is inconclusive evidence that some medical conditions, such as otitis media, infections, epilepsy, gastrointestinal problems, birth complications, and delay in developmental and physiological milestones, may be associated with ASD, but may manifest well before the onset of hallmark behavioral symptoms of ASD. Despite the fact that individually these medical symptoms may not be sensitive enough to be used as a viable marker for ASD diagnosis, combined together, they hold the promise of robustly determining children’s risks for ASD well before any existing ASD screening tool is currently capable of. The elimination of delayed diagnosis would allow for optimization of outcomes through early intervention. To the best of our knowledge, there has been little research to harvest this accumulated knowledge. By leveraging a large, national, longitudinal, private insurance medical claims database (MarketScan®) and Medicaid claims database (Medicaid Analytic eXtract or MAX), we will comprehensively investigate the collective role of certain medical symptoms and healthcare service use patterns as early markers for predicting ASD risk. If successful, this study will demonstrate a novel way of improving ASD risk prediction, upon which we can construct a medical claims-based ASD surveillance system. Working in the background, such a system can sift through an extensive volume of children’s electronic medical claims records, looking for patterns indicating potential risk and identifying children for further in-person evaluations when their ASD risk has crossed a critical threshold. This would ultimately advance ASD early detection and thus ultimately improve the impact of early intervention therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The interplay of behavioral therapies, pharmacological treatments and psychiatric adverse events among Youth with Autism Spectrum Disorders
Nanoparticle-Powered Chemiluminescent Lateral Flow Biosensor Array for Early Diagnosis of Pancreatic Cancer
  • 批准号:
    8813061
  • 项目类别:
  • 资助金额:
    $23.27万
  • 财政年份:
    2016
  • 负责人:
    Guodong Liu
  • 依托单位:
Development of a Hand-Held Cancer Biomarker Monitor
  • 批准号:
    8127853
  • 项目类别:
  • 资助金额:
    $18.17万
  • 财政年份:
    2010
  • 负责人:
    Guodong Liu
  • 依托单位:
Development of a Hand-Held Cancer Biomarker Monitor
  • 批准号:
    7871157
  • 项目类别:
  • 资助金额:
    $15.61万
  • 财政年份:
    2010
  • 负责人:
    Guodong Liu
  • 依托单位:
海外基金